Innovations in artificial intelligence and precision medicine in the field of cancer treatment are helping to target therapies and improve patient chances.
Medical technology pioneer Tempus has launched EDGE, a ground-breaking platform that allows pathologists to access developing AI models intended to identify specimens with potentially actionable biomarkers. A biomarker is an indicator of the progress of a disease.
“We believe there is a unique opportunity to advance patient care by integrating digital pathology AI tools into our daily clinical practice,” said Matthew Leavitt, MD, CEO of PathNet Labs, a US-based network of digital pathology practices that is working with Tempus. “We will carefully validate safe-use clinical applications of Tempus technology while empowering our pathologists with computational tools that can assist in identifying patients most likely to benefit from new therapies.”
With access to over 50 petabytes of multimodal data, Tempus is developing AI models with the aim of identifying patients who would benefit the most, including those in clinical trials, helping this to happen earlier in their cancer care journey.
Tempus is creating a network of pathology labs, called NAPA, across the US that can access the company’s growing portfolio of investigational AI models designed to identify patients that are more likely to have targetable biomarkers. In addition, Tempus is collaborating with some of the world’s leading pharmaceutical and biotech companies to leverage the EDGE platform and NAPA network to identify unique biomarkers and co-develop novel AI applications.